Maplight Therapeutics holder plans 48,158-share stock sale

Maplight Therapeutics, Inc. has a planned sale of 48,158 common shares of its stock through Jefferies LLC, with an indicated sale date of July 15, 2026 on NASDAQ.

Rhea-AI Filing Summary

Maplight Therapeutics, Inc. has a planned sale of 48,158 common shares of its stock through Jefferies LLC, with an indicated sale date of July 15, 2026 on NASDAQ. The shares have an aggregate market value of $1,825,669.78, while 42,620,000 shares are outstanding. The seller, Erin Pennock Foff, acquired Maplight shares via restricted stock unit grants on several dates and has already sold multiple blocks of shares between April 15 and May 7, 2026, including 24,052 shares on May 6, 2026 for $691,814.17.

Key Figures

Planned shares to be sold: 48,158 shares Aggregate market value: $1,825,669.78 Shares outstanding: 42,620,000 shares +3 more

6 metrics

Planned shares to be sold 48,158 shares Number of Maplight Therapeutics common shares planned for sale

Aggregate market value $1,825,669.78 Aggregate market value of the 48,158 shares to be sold

Shares outstanding 42,620,000 shares Maplight Therapeutics common shares outstanding

Indicated sale date 07/15/2026 Indicated date for the planned share sale

Recent sale on May 6, 2026 24,052 shares for $691,814.17 One of several recent sales by Erin Pennock Foff

RSU grant on July 18, 2025 60,346 units Restricted stock unit grant in Maplight Therapeutics common stock

Key Terms

Form 144, restricted stock unit, aggregate market value, Securities To Be Sold, +1 more

5 terms

Form 144 regulatory

"144: Securities Information"

Form 144 is a document that investors must file with the government when they plan to sell a large number of shares of a company's stock. It helps ensure transparency so everyone knows how many shares are being sold and when, which can impact the stock's price.

restricted stock unit financial

"Restricted Stock Unit Grant | Maplight Therapeutics, Inc."

A restricted stock unit is a promise from a company to give an employee shares of stock after certain conditions are met, like staying with the company for a set amount of time. It’s like earning a bonus that turns into company stock once you’ve proven your commitment, making it a way to motivate and reward employees.

aggregate market value financial

"Common | Jefferies LLC ... | 48158 | 1825669.78 | 42620000"

Aggregate market value is the combined price you would pay to buy all outstanding shares of a company or all companies in a group at current market prices — essentially the sum of each stock’s market capitalization. It matters to investors because it shows the overall size and weight of an investment or sector (like the total cost to buy every piece of a puzzle), helps compare scale across companies or markets, and influences index composition and risk exposure.

Securities To Be Sold regulatory

"144: Securities To Be Sold"

Securities Sold During The Past 3 Months regulatory

"144: Securities Sold During The Past 3 Months"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What share sale is disclosed for Maplight Therapeutics (MPLT) in this Form 144?

The filing shows a planned sale of 48,158 common shares of Maplight Therapeutics through Jefferies LLC. The aggregate market value of these shares is $1,825,669.78, with trading indicated on NASDAQ and an expected sale date of July 15, 2026.

How many Maplight Therapeutics (MPLT) shares are outstanding in this filing?

The Form 144 lists 42,620,000 shares of Maplight Therapeutics outstanding. This figure provides context for the planned sale of 48,158 shares, helping investors gauge the relative size of the transaction versus the company’s total common shares.

Who is the selling shareholder in the Maplight Therapeutics (MPLT) Form 144?

The selling holder is listed as Erin Pennock Foff, with an address at 800 Chesapeake Drive, Redwood City, CA 94063. The filing details both the planned sale of 48,158 shares and several prior sales in April and May 2026.

What recent Maplight Therapeutics (MPLT) share sales has Erin Pennock Foff made?

Recent sales include 24,052 shares on May 6, 2026 for $691,814.17, 15,652 shares on May 4, 2026 for $437,576.39, and additional smaller blocks between April 15 and May 7, 2026, each with disclosed proceeds.

How were the Maplight Therapeutics (MPLT) shares being sold acquired?

The shares were acquired through restricted stock unit grants in Maplight Therapeutics, Inc. Grants include 60,346 units dated July 18, 2025 and smaller grants on July 30, 2023, November 9, 2023, and May 2, 2024, all referencing Maplight common stock.

Which broker is handling the planned Maplight Therapeutics (MPLT) share sale?

The broker listed is Jefferies LLC, located at 520 Madison Avenue, 4th Floor, New York, NY 10022. Jefferies is identified in connection with the planned sale of 48,158 Maplight Therapeutics common shares on NASDAQ.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 07/15/2026 - 04:44 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0002021233
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	MapLight Therapeutics, Inc.
SEC File Number	001-42914
Address of Issuer	800 CHESAPEAKE DRIVE REDWOOD CITY CALIFORNIA 94063
Phone	617-984-6300
Name of Person for Whose Account the Securities are To Be Sold	Foff Erin Pennock
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Jefferies LLC 520 Madison Avenue, 4th Floor New York NY 10022	48158	1825669.78	42620000	07/15/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	07/30/2023	Restricted Stock Unit Grant	Maplight Therapeutics, Inc.			3349	07/30/2023	N/A
Common	07/18/2025	Restricted Stock Unit Grant	Maplight Therapeutics, Inc.			60346	07/18/2025	N/A
Common	05/02/2024	Restricted Stock Unit Grant	Maplight Therapeutics, Inc.			6351	05/02/2024	N/A
Common	11/09/2023	Restricted Stock Unit Grant	Maplight Therapeutics, Inc.			1546	11/09/2023	N/A

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Erin Pennock Foff 800 Chesapeake Drive Redwood City CA 94063	Common	05/07/2026	4438	126629.81
Erin Pennock Foff 800 Chesapeake Drive Redwood City CA 94063	Common	05/06/2026	24052	691814.17
Erin Pennock Foff 800 Chesapeake Drive Redwood City CA 94063	Common	05/05/2026	10576	298207.77
Erin Pennock Foff 800 Chesapeake Drive Redwood City CA 94063	Common	05/04/2026	15652	437576.39
Erin Pennock Foff 800 Chesapeake Drive Redwood City CA 94063	Common	04/16/2026	1169	31997.52
Erin Pennock Foff 800 Chesapeake Drive Redwood City CA 94063	Common	04/15/2026	2044	54869.99

144: Remarks and Signature

Remarks	1) A portion of the shares being sold is pursuant to a Rule 10b5-1 Trading Plan adopted on December 29, 2025. All representations regarding the absence of material non-public information were made at the time the plan was adopted. 2) The remaining shares to be sold is solely to satisfy tax withholding obligations arising from RSU vesting.
Date of Notice	07/15/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	12/29/2025
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	Erin Foff
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)